Fosun Pharma (02196.HK) intends to participate in the investment establishment of Star Rise Jing Xuan, a nuclear medicine business platform company.

date
23/07/2025
Wisdom Finance and Economics APP news, Fosun Pharma (02196.HK) issued an announcement to further enrich the group's innovative product pipeline by setting up a nuclear medicine business platform company, Xingrui Jingxuan (the new company), to layout the core pharmaceutical product track. At the same time, in order to fully mobilize the enthusiasm and creativity of the core team of the company, enhance team cohesion and core competitiveness, the company (or its controlling subsidiary) intends to participate in the investment and establish the new company at the same time to implement the company's follow-up investment, and adopt the initial incentive plan after the establishment of the new company.